NCT05451212 2025-11-10
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Cabaletta Bio
Phase 1 Completed
Clinical Trials
6 trialsNCT02112526 2024-12-20
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 1 Completed
NCT02658968 2024-01-16
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Nordic Nanovector
Phase 1 Completed
NCT00772486 2021-09-22
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Memgen, Inc.
Phase 1 Completed
NCT00783588 2008-10-31
A Phase I Extension Trial of Repeated Infusions of ISF35
Memgen, Inc.
Phase 1 Completed
NCT00779883 2008-10-24
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Memgen, Inc.
Phase 1 Completed